Table 3. Uni- and multivariate analyses for the presence of BRAF mutation in the population of RAS-wt patients.

	TS (N=281)				VS (N=262)
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
Gender
F vs M	2.78 (1.51–5.11)	0.001	2.90 (1.14–7.37)	0.025	2.31 (1.23–4.33)	0.009	1.92 (0.92–3.97)	0.08
Age (cut-off: 65 years)
⩾65 vs <65	1.03 (1.00–1.06)	0.030	–	0.11	1.42 (0.76–2.68)	0.27	–	–
ECOG-PS
⩾2 vs <2	2.09 (1.02–4.28)	0.044	–	0.87	1.30 (0.54–3.12)	0.55	–	–
Synchronous metastases
yes vs no	1.17 (0.63–2.19)	0.606	–	–	1.34 (0.72–2.50)	0.35	–	-
Primary site
right vs left	7.12 (3.74–13.56)	0.0001	7.80 (3.05–19.92)	<0.0001	11.14 (5.50–22.56)	<0.0001	8.68 (4.18–18.02)	<0.0001
Primary resected
no vs yes	1.43 (0.68–3.02)	0.339	–	–	1.29 (0.78–2.86)	0.229	–	-
Mucinous histology
yes vs no	4.69 (2.33–9.46)	0.0001	4.95 (1.90–12.90)	<0.0001	4.61 (2.34–9.07)	<0.0001	3.23 (1.49–7.02)	0.003
Number of metastatic site
>1 vs 1	1.21 (0.68–2.14)	0.506	–	–	1.92 (1.03–3.60)	0.04	–	0.34
Peritoneal metastases
yes vs no	2.19 (1.15–4.19)	0.017	–	0.17	2.53 (1.27–5.02)	0.01	–	0.15
Lung metastases
yes vs no	1.22 (0.59–2.51)	0.586	–	–	1.12 (0.65–1.91)	0.69	–	–
Distant lymp-node metastases
yes vs no	2.02 (1.05–3.88)	0.009	–	0.64	3.30 (1.72–6.33)	<0.0001	–	0.19
Tumour grading
3–4 vs 1–2	4.54 (2.18–9.48)	0.0001	–	0.46	1.63 (0.85–3.13)	0.14	–	–

Abbreviations: CI=confidence intervals; N=number; OR=odds ratio; PS=performance status; TS=training set; VS=validation set; wt=wild type.